Selected research
Industry Research
Dermatological Disorders Medications Industry Research Report 2026
Market perspective
The global Dermatological Disorders Medications market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Dermatological Disorders Medications is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Dermatological Disorders Medications is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Dermatological Disorders Medications is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Dermatological Disorders Medications include Novartis, Mylan Pharmaceuticals, Roche, Pfizer, GlaxoSmithKline, Sinclair Pharma, PharmaDerm, Galderma and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Dermatological Disorders Medications market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Dermatological Disorders Medications Market by Company
Novartis
Mylan Pharmaceuticals
Roche
Pfizer
GlaxoSmithKline
Sinclair Pharma
PharmaDerm
Galderma
Bristol-Myers Squibb
Bausch Health
Barrier Therapeutics
Almirall
Dermatological Disorders Medications Segment by Type
Prescription Drugs
Over-The-Counter Drugs
Dermatological Disorders Medications Segment by Application
Online Pharmacies
Hospital Pharmacies
Retail Pharmacies
Dermatological Disorders Medications Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatological Disorders Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dermatological Disorders Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatological Disorders Medications.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Dermatological Disorders Medications manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Dermatological Disorders Medications by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Dermatological Disorders Medications in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Prescription Drugs
- Over-The-Counter Drugs
Applications
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
Companies covered
- Novartis
- Mylan Pharmaceuticals
- Roche
- Pfizer
- GlaxoSmithKline
- Sinclair Pharma
- PharmaDerm
- Galderma
- Bristol-Myers Squibb
- Bausch Health
- Barrier Therapeutics
- Almirall
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Dermatological Disorders Medications Market Size (2021-2032)
- 2.2.2 Global Dermatological Disorders Medications Sales (2021-2032)
- 2.2.3 Global Dermatological Disorders Medications Market Average Price (2021-2032)
- 2.3 Dermatological Disorders Medications by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Prescription Drugs
- 2.3.3 Over-The-Counter Drugs
- 2.4 Dermatological Disorders Medications by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Online Pharmacies
- 2.4.3 Hospital Pharmacies
- 2.4.4 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Dermatological Disorders Medications Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Dermatological Disorders Medications Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Dermatological Disorders Medications Revenue of Manufacturers (2021-2026)
- 3.4 Global Dermatological Disorders Medications Average Price by Manufacturers (2021-2026)
- 3.5 Global Dermatological Disorders Medications Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Dermatological Disorders Medications, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Dermatological Disorders Medications, Product Type & Application
- 3.8 Global Manufacturers of Dermatological Disorders Medications, Established Date
- 3.9 Global Dermatological Disorders Medications Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis
- 4.1.1 Novartis Company Information
- 4.1.2 Novartis Business Overview
- 4.1.3 Novartis Dermatological Disorders Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis Dermatological Disorders Medications Product Portfolio
- 4.1.5 Novartis Recent Developments
- 4.2 Mylan Pharmaceuticals
- 4.2.1 Mylan Pharmaceuticals Company Information
- 4.2.2 Mylan Pharmaceuticals Business Overview
- 4.2.3 Mylan Pharmaceuticals Dermatological Disorders Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Mylan Pharmaceuticals Dermatological Disorders Medications Product Portfolio
- 4.2.5 Mylan Pharmaceuticals Recent Developments
- 4.3 Roche
- 4.3.1 Roche Company Information
- 4.3.2 Roche Business Overview
- 4.3.3 Roche Dermatological Disorders Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Roche Dermatological Disorders Medications Product Portfolio
- 4.3.5 Roche Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Dermatological Disorders Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Dermatological Disorders Medications Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 GlaxoSmithKline
- 4.5.1 GlaxoSmithKline Company Information
- 4.5.2 GlaxoSmithKline Business Overview
- 4.5.3 GlaxoSmithKline Dermatological Disorders Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GlaxoSmithKline Dermatological Disorders Medications Product Portfolio
- 4.5.5 GlaxoSmithKline Recent Developments
- 4.6 Sinclair Pharma
- 4.6.1 Sinclair Pharma Company Information
- 4.6.2 Sinclair Pharma Business Overview
- 4.6.3 Sinclair Pharma Dermatological Disorders Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sinclair Pharma Dermatological Disorders Medications Product Portfolio
- 4.6.5 Sinclair Pharma Recent Developments
- 4.7 PharmaDerm
- 4.7.1 PharmaDerm Company Information
- 4.7.2 PharmaDerm Business Overview
- 4.7.3 PharmaDerm Dermatological Disorders Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 PharmaDerm Dermatological Disorders Medications Product Portfolio
- 4.7.5 PharmaDerm Recent Developments
- 4.8 Galderma
- 4.8.1 Galderma Company Information
- 4.8.2 Galderma Business Overview
- 4.8.3 Galderma Dermatological Disorders Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Galderma Dermatological Disorders Medications Product Portfolio
- 4.8.5 Galderma Recent Developments
- 4.9 Bristol-Myers Squibb
- 4.9.1 Bristol-Myers Squibb Company Information
- 4.9.2 Bristol-Myers Squibb Business Overview
- 4.9.3 Bristol-Myers Squibb Dermatological Disorders Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Bristol-Myers Squibb Dermatological Disorders Medications Product Portfolio
- 4.9.5 Bristol-Myers Squibb Recent Developments
- 4.10 Bausch Health
- 4.10.1 Bausch Health Company Information
- 4.10.2 Bausch Health Business Overview
- 4.10.3 Bausch Health Dermatological Disorders Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bausch Health Dermatological Disorders Medications Product Portfolio
- 4.10.5 Bausch Health Recent Developments
- 4.11 Barrier Therapeutics
- 4.11.1 Barrier Therapeutics Company Information
- 4.11.2 Barrier Therapeutics Business Overview
- 4.11.3 Barrier Therapeutics Dermatological Disorders Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Barrier Therapeutics Dermatological Disorders Medications Product Portfolio
- 4.11.5 Barrier Therapeutics Recent Developments
- 4.12 Almirall
- 4.12.1 Almirall Company Information
- 4.12.2 Almirall Business Overview
- 4.12.3 Almirall Dermatological Disorders Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Almirall Dermatological Disorders Medications Product Portfolio
- 4.12.5 Almirall Recent Developments
5 Global Dermatological Disorders Medications Market Scenario by Region
- 5.1 Global Dermatological Disorders Medications Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Dermatological Disorders Medications Sales by Region: 2021-2032
- 5.2.1 Global Dermatological Disorders Medications Sales by Region: 2021-2026
- 5.2.2 Global Dermatological Disorders Medications Sales by Region: 2027-2032
- 5.3 Global Dermatological Disorders Medications Revenue by Region: 2021-2032
- 5.3.1 Global Dermatological Disorders Medications Revenue by Region: 2021-2026
- 5.3.2 Global Dermatological Disorders Medications Revenue by Region: 2027-2032
- 5.4 North America Dermatological Disorders Medications Market Facts & Figures by Country
- 5.4.1 North America Dermatological Disorders Medications Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Dermatological Disorders Medications Sales by Country (2021-2032)
- 5.4.3 North America Dermatological Disorders Medications Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Dermatological Disorders Medications Market Facts & Figures by Country
- 5.5.1 Europe Dermatological Disorders Medications Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Dermatological Disorders Medications Sales by Country (2021-2032)
- 5.5.3 Europe Dermatological Disorders Medications Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Dermatological Disorders Medications Market Facts & Figures by Country
- 5.6.1 Asia Pacific Dermatological Disorders Medications Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Dermatological Disorders Medications Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Dermatological Disorders Medications Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Dermatological Disorders Medications Market Facts & Figures by Country
- 5.7.1 South America Dermatological Disorders Medications Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Dermatological Disorders Medications Sales by Country (2021-2032)
- 5.7.3 South America Dermatological Disorders Medications Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Dermatological Disorders Medications Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Dermatological Disorders Medications Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Dermatological Disorders Medications Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Dermatological Disorders Medications Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Dermatological Disorders Medications Sales by Type (2021-2032)
- 6.1.1 Global Dermatological Disorders Medications Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Dermatological Disorders Medications Sales Market Share by Type (2021-2032)
- 6.2 Global Dermatological Disorders Medications Revenue by Type (2021-2032)
- 6.2.1 Global Dermatological Disorders Medications Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Dermatological Disorders Medications Revenue Market Share by Type (2021-2032)
- 6.3 Global Dermatological Disorders Medications Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Dermatological Disorders Medications Sales by Application (2021-2032)
- 7.1.1 Global Dermatological Disorders Medications Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Dermatological Disorders Medications Sales Market Share by Application (2021-2032)
- 7.2 Global Dermatological Disorders Medications Revenue by Application (2021-2032)
- 7.2.1 Global Dermatological Disorders Medications Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Dermatological Disorders Medications Revenue Market Share by Application (2021-2032)
- 7.3 Global Dermatological Disorders Medications Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Dermatological Disorders Medications Value Chain Analysis
- 8.1.1 Dermatological Disorders Medications Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Dermatological Disorders Medications Production Mode & Process
- 8.2 Dermatological Disorders Medications Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Dermatological Disorders Medications Distributors
- 8.2.3 Dermatological Disorders Medications Customers
9 Global Dermatological Disorders Medications Analyzing Market Dynamics
- 9.1 Dermatological Disorders Medications Industry Trends
- 9.2 Dermatological Disorders Medications Industry Drivers
- 9.3 Dermatological Disorders Medications Industry Opportunities and Challenges
- 9.4 Dermatological Disorders Medications Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst